Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating

Olema Pharmaceuticals (NASDAQ:OLMA) is one of the 17 biotechnology stocks with more than 50% upside.

On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA). She assigned a Buy rating to the stock with a $48 price target, which leads to more than 102% upside potential for investors.

Pressmaster/Shutterstock.com

Using a conservative approach, Prendergast has modeled peak sales for palazestrant at $3.1 billion in 2035. She also noted that endocrine therapy in ER+HER2 can be “a $20B+ global market opportunity with plenty of room for many big players.”

On January 7, Michael Yee of UBS also initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA), assigning a Buy rating and a $48 price target. He based his rating on a more favorable outlook for the biotech segment after what he described as a “rough period.” Yee expects greater investor confidence in the segment, which should drive better performance in 2026.

Olema Pharmaceuticals (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for women’s cancers. They commercialize next-gen breast cancer therapies, particularly targeting ER+/HER2- cancer. Its lead program is Palazestrant (OP-1250) to cure metastatic breast cancer, which is currently in Phase 3 clinical trials.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.